Indicators
Indicators
Value
Direction
MACD(12,26,9)
1.612
Buy
RSI(14)
56.835
Neutral
STOCH(KDJ)(9,3,3)
78.286
Neutral
ATR(14)
3.595
High Vlolatility
CCI(14)
105.848
Buy
Williams %R
22.368
Buy
TRIX(12,20)
0.092
Sell
StochRSI(14)
41.117
Sell
AbbVie Inc
ABBVView Detailed Chart
191.080USD
-1.420-0.74%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
337.50BMarket Cap
79.64P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.74%
5 Days
+0.66%
1 Month
+7.69%
6 Months
+10.22%
Year to Date
+7.53%
1 Year
+13.34%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
28
analysts
BUY
Current Rating
211.654
Target Price
10.77%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
167
Total
5
Median
8
Average
Company name
Ratings
Analysts
AbbVie Inc
ABBV
28
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
34
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Buy
Moving Average
Indicators
Value
Direction
MA5
190.732
Buy
MA10
189.254
Buy
MA20
186.763
Buy
MA50
185.092
Buy
MA100
192.148
Sell
MA200
188.857
Buy
News
Berenberg raises AbbVie PT on higher immunology drug sales
** Berenberg raises PT on drugmaker AbbVie ABBV.N to $195 from $165, citing higher immunology drug sales ** New PT is a 8.7% downside to stock's last close** Brokerage says AbbVie knows the autoimmune market well ** Says co reduced exposure to antirheumatic drug Humira and bolstered cash flows t...
ReutersWed, Mar 12
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
Feb 7 (Reuters) - AbbVie ABBV.N said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria.AbbVie and co-developer Pfizer's PFE.N drug, Emblaveo, is approved in combination with an...
ReutersFri, Feb 7
Company
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Ticker SymbolABBV
CompanyAbbVie Inc
CEOMr. Robert A. Michael, CPA
Websitehttps://www.abbvie.com/
Related Instruments
+0.90%
+0.28%
-1.44%
-1.09%
-0.77%
-0.09%
-0.70%
-1.23%
-1.15%
-2.28%
-1.00%
-1.82%
-1.32%
-0.36%
-3.87%
-2.66%
+1.09%
+0.54%
-1.17%
-4.07%
